Home Premarket Biotech Digest: Exelixis' Milestone, Valeant's Investor Call, Sophiris Soars
 

Keywords :   


Premarket Biotech Digest: Exelixis' Milestone, Valeant's Investor Call, Sophiris Soars

2015-11-12 05:49:58| Biotech - Topix.net

Click this link to find out how much you can save.) Exelixis achieved a major milestone on Tuesday as the company's Cotellic was approved by the FDA as a treatment for patients with BRAF V600E or V600K mutation-positive unresectable or metastatic melanoma in combination with Zelboraf. Cotellic has already been approved in Switzerland earlier this year.

Tags: call investor digest biotech

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news

»
05.11Boeing strike ends as workers back 38% pay rise deal
05.11Tropical Storm Rafael Public Advisory Number 6A
05.11Summary for Tropical Storm Rafael (AT3/AL182024)
05.11Tropical Storm Rafael Graphics
05.11Atlantic Tropical Weather Outlook
05.11Eastern North Pacific Tropical Weather Outlook
05.11Tropical Storm Rafael Graphics
05.11Tropical Storm Rafael Forecast Discussion Number 6
More »